Myc-Transformed Epithelial Cells Down-Regulate Clusterin, Which Inhibits Their Growth in Vitro and Carcinogenesis in Vivo

Cancer Research

Volumn 64, Issue 9, 2004, Pages 3126-3136

  Thomas Tikhonenko, Andrei ^a   Viard Leveugle, Isabelle ^b,c   Dews, Michael ^a   Wehrli, Philippe ^b   Sevignani, Cinzia ^a   Yu, Duonan ^a   Ricci, Stacey ^a   El Deiry, Wafik ^a   Aronow, Bruce ^d   Kaya, Gürkan ^b   Saurat, Jean Hilaire ^b   French, Lars E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c IVL BioService ^*  (France)

^d CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CLUSTERIN; COMPLEMENTARY DNA; COMPLEMENTARY RNA; DIMETHYLBENZ[A]ANTHRACENE; GLYCOPROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; COLON; CONTROLLED STUDY; DNA REPLICATION; DOSE RESPONSE; DOWN REGULATION; EMBRYO; EPITHELIUM CELL; GENE CONTROL; GENE EXPRESSION REGULATION; GENETIC CODE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CELL; KERATINOCYTE; MOUSE; MOUSE STRAIN; NONHUMAN; NULL ALLELE; ONCOGENE MYC; PAPILLOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; WILD TYPE;

ANIMALS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CLUSTERIN; DOWN-REGULATION; EPITHELIAL CELLS; GENES, MYC; GLYCOPROTEINS; HUMANS; KERATINOCYTES; MICE; MICE, KNOCKOUT; MOLECULAR CHAPERONES; RECOMBINANT PROTEINS; SKIN NEOPLASMS; THROMBOSPONDIN 1;

EID: 2342571717     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1953     Document Type: Article

References (97)

1. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Ann Rev Cell Dev Biol 2000;16:653-99.
2. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. Sequence-specific DNA binding by the c-myc protein. Science (Wash. DC) 1990;250:1149-51.
3. Kretzner L, Blackwood EM, Eisenman RN. Myc and Max proteins possess distinct transcriptional activities. Nature (Lond.) 1992;359:426-9.
4. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature (Lond.) 1992;359:423-6.
5. McMahon SB, Van BA, Dugan KA, Copeland TD, Cole MD. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 1998;94:363-74.
6. McMahon SB, Wood MA, Cole MD. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 2000;20:556-62.
7. Amati B, Frank SR, Donjerkovic D, Taubert S. Function of the c-Myc oncoprotein in chromatin remodeling and transcription. Biochim Biophys Acta 2001;1471:M135-45.
8. Li L, Nerlov C, Prendergast GC, Ziff EB. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J 1994;13:4070-9.
9. Staller P, Peukert K, Kiermaier A, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001;3:392-9.
10. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: marvelously complex. Adv Cancer Res 2002;84:81-154.
11. O'Connell BC, Cheung AF, Simkevich CP, et al. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 2003;278:12563-73.
12. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993;90:7804-8.
13. Jansen-Durr P, Meichle A, Steiner P, et al. Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci USA 1993;90:3685-9.
14. Galaktionov K, Chen X, Beach D. cdc25 cell cycle phosphatase as a target of c-myc. Nature (Lond.) 1996;382:511-7.
15. Hermeking H, Rago C, Schuhmacher M, et al. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA 2000;97:2229-34.
16. Lasorella A, Noseda M, Beyna M, Iavarone A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature (Lond.) 2000;407:592-8.
17. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev 1998;12:1769-74.
18. Philipp A, Schneider A, Vasrik I, et al. Repression of cyclin D1: a novel function of MYC. Mol Cell Biol 1994;14:4032-43.
19. Mitchell KO, El-Deiry WS. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ 1999;10:223-30.
20. Claassen GF, Hann SR. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor β-induced cell cycle arrest. Proc Natl Acad Sci USA 2000;97:9498-503.
21. Gartel AL, Ye X, Goufman E, et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 2001;98:4510-5.
22. Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massague J. TGF-β influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol 2001;3:400-8.
23. Marhin WW, Chen S, Facchini LM, Fornace AJ, Penn LZ. Myc represses the growth arrest gene gadd45. Oncogene 1997;14:2825-34.
24. Lee TC, Li L, Philipson L, Ziff EB. Myc represses transcription of the growth arrest gene gas1. Proc Natl Acad Sci USA 1997;94:12886-91.
25. Eilers M, Picard D, Yamamoto KR, Bishop JM. Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature (Lond.) 1989;340:66-8.
26. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 1997;8:1039-48.
27. Johnston LA, Prober DA, Edgar BA, Eisenman RN, Gallant P. Drosophila myc regulates cellular growth during development. Cell 1999;98:779-90.
28. Trumpp A, Refaeli Y, Oskarsson T, et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature (Lond.) 2001;414:768-73.
29. Tikhonenko AT, Black DJ, Linial ML. Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J Biol Chem 1996;271:30741-7.
30. Janz A, Sevignani C, Kenyon K, Ngo C, Thomas-Tikhonenko A. Activation of the Myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Res 2000;28:2268-75.
31. Guo N, Templeton NS, Al-Barazi H, et al. Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. Cancer Res 2000;60:457-66.
32. Armstrong LC, Bjorkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P. Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 2002;13:1893-905.
33. Tomii Y, Kamochi J, Yamazaki H, et al. Human thrombospondin 2 inhibits proliferation of microvascular endothelial cells. Int J Oncol 2002;20:339-42.
34. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002;6:1-12.
35. Ngo C, Gee MS, Akhtar N, et al. An in vivo function for the transforming myc protein: elicitation of the angiogenic phenotype. Cell Growth Differ 2000;11:201-10.
36. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003;3:219-31.
37. Brandvold KA, Neiman P, Ruddell A. Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene 2000;19:2780-5.
38. Pelengaris S, Littlewood T, Khan M, Elia G, Evan GI. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999;3:565-77.
39. Zeller KI, Jegga AG, Aronow B, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 2003;4:R69.1-10.
40. Louro ID, Bailey EC, Li X, et al. Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation. Cancer Res 2002;62:5867-73.
41. Jenne DE, Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 1992;17:154-9.
42. Rosenberg M, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995;27:633-45.
43. Blaschuk O, Burdzy K, Fritz IB. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem 1983;258:7714-20.
44. Fritz IB, Burdzy K, Setchell B, Blaschuk O. Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro. Biol Reprod 1983;28:1173-88.
45. Tung PS, Burdzy K, Wong K, Fritz IB. Competition between cell-substratum interactions and cell-cell interactions. J Cell Physiol 1992;152:410-21.
46. Choi NH, Mazda T, Tomita M. A serum protein SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes. Mol Immunol 1989;26:835-40.
47. Jenne DE, Tschopp J. Molecular structure and functional characterization of a novel human cytolysis inhibitor (CLI) found in blood and seminal plasma. Identity to sulfated glycoprotein 2 (SGP-2), a constituent of rat testis fluid. Proc Natl Acad Sci USA 1989;86:7123-7.
48. Kirszbaum L, Sharpe JA, Murphy B, et al. Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems. EMBO J 1989;8:711-8.
49. de Silva HV, Stuart WD, Duvic CR, et al. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem 1990;265:13240-7.
50. James RW, Hochstrasser AC, Borghini I, Martin B, Pometta D, Hochstrasser D. Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytolysis. Arterioscler Thromb 1991;11:645-52.
51. Jenne DE, Lowin B, Peitsch MC, Böttcher A, Schmitz G, Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 1991;266:11030-6.
52. French LE, Wohlwend A, Sappino AP, Tschopp J, Schifferli JA. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J Clin Investig 1994;93:877-84.
53. Schwochau GB, Nath KA, Rosenberg ME. Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int 1998;53:1647-53.
54. Viard I, Wehrli P, Jornot L, et al. Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J Investig Dermatol 1999;112:290-6.
55. Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 2000;25:95-8.
56. Yang CR, Leskov K, Hosley-Eberlein K, et al. Nuclear clusterin/XIP8, an X-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci USA 2000;97:5907-12.
57. Criswell T, Klokov D, Beman M, Lavik JP, Boothman DA. Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein. Cancer Biol Ther 2003;2:372-80.
58. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003;278:11590-600.
59. Diemer V, Hoyle M, Baglioni C, Millis A. Expression of porcine complement inhibitor mRNA in cultured aortic smooth muscle cells: changes during differentiation in vitro. J Biol Chem 1992;267:5257-64.
60. French LE, Chonn A, Ducrest D, et al. Murine clusterin: molecular cloning and mRNA localization of a gene associated with epithelial differentiation processes during embryogenesis. J Cell Biol 1993;122:1119-30.
61. Seiberg M, Marthinuss J. Clusterin expression within skin correlates with hair growth. Dev Dyn 1995;202:294-301.
62. Sevignani C, Wlodarski P, Kirillova J, et al. Tumorigenic conversion of p53-deficient colon epithelial cells by an activated Ki-ras gene. J Clin Investig 1998;101:1572-80.
63. Fidler IJ. Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev 1991;10:229-43.
64. McLaughlin L, Mistry M, Zhu G, et al. Apolipoprotein J/Clusterin limits the severity of murine autoimmune myocarditis. J Clin Investig 2000;106:1105-13.
65. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998;92:3780-92.
66. Limat A, Hunziker T, Boillat C, Bayreuther K, Noser F. Post-mitotic human dermal fibroblasts efficiently support the growth of human follicular keratinocytes. J Investig Dermatol 1989;92:758-62.
67. Limat A, Noser F. Serial cultivation of single keratinocytes from the outer root sheath of human scalp hair follicles. J Investig Dermatol 1986;87:485-8.
68. Giard DJ, Aaronson S, Todaro GJ, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst (Bethesda) 2003;51:1417-23.
69. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74.
70. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95:2509-14.
71. Hennings H, Glick AB, Lowry DT, et al. FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 1993;14:2353-8.
72. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995;23:1686-90.
73. Blackwood EM, Lugo TG, Kretzner L, et al. Functional analysis of the AUG- and CUG-initiated forms of the c-Myc protein. Mol Biol Cell 1994;5:597-609.
74. Adams JC, Tucker RP. The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development. Dev Dyn 2000;218:280-99.
75. Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type 1 repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997;57:1735-42.
76. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999;100:1423-31.
77. Claassen GF, Hann SR. Myc-mediated transformation: the repression connection. Oncogene 1999;18:2925-33.
78. Cerezo A, Stark HJ, Moshir S, Boukamp P. Constitutive overexpression of human telomerase reverse transcriptase but not c-myc blocks terminal differentiation in human HaCaT skin keratinocytes. J Investig Dermatol 2003;121:110-9.
79. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
80. Amati B. Integrating Myc and TGF-β signalling in cell-cycle control. Nat Cell Biol 2001;3:E112-3.
81. Gumienny TL, Padgett RW. The other side of TGF-β superfamily signal regulation: thinking outside the cell. Trends Endocrinol Metabol 2002;13:295-9.
82. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 1998;93:1159-70.
83. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor β. J Biol Chem 1999;274:13586-93.
84. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol 2000;19:597-614.
85. Petropoulo C, Trougakos I, Kolettas E, Toussaint O, Gonos E. Clusterin/apolipoprotein J is a novel biomarker of cellular senescence that does not affect the proliferative capacity of human diploid fibroblasts. FEBS Lett 2001;509:287-97.
86. Zhou W, Janulis L, Park II, Lee C. A novel anti-proliferative property of clusterin in prostate cancer cells. Life Sci 2002;72:11-21.
87. Bettuzzi S, Scorcioni F, Astancolle S, Davalli P, Scaltriti M, Corti A. Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene 2002;21:4328-34.
88. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992;54:63-128.
89. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol. 2000;157:393-9.
90. Parczyk K, Pilarsky C, Rachel U, Koch BC. Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol 1994;120:186-8.
91. Steinberg J, Oyasu R, Lang S, et al. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997;3:1707-11.
92. Dai CY, Furth EE, Mick R, et al. p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 2000;119:929-42.
93. Miyake H, Gleave M, Arakawa S, Kamidono S, Hara I. Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential. J Urol 2002;167:2203-8.
94. Cui W, Fowlis DJ, Bryson S, et al. TGF-β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996;86:531-42.
95. Qian X, Tuszynski GP. Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med 1996;212:199-207.
96. Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 2001;7: 4245-52.
97. Gleave ME, Miyake H, Zellweger T, et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 2001; 58:39-49.